Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

about

Synthesis and Antitumor Activity of Triazole-Containing Sorafenib Analogs.

P2860

Q50075645-53C9AF02-35F0-4C1B-B543-DA7654010DE3

P2860

Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

Item

http://www.wikidata.org/entity/Q38710796

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

@en

type

Item

label

Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

@en

prefLabel

Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

@en

P1476

Rational drug design of indazole-based diarylurea derivatives as anticancer agents

@en

P2093

Chang-Jun Sun

http://www.w3.org/2001/XMLSchema#string

Gang Li

http://www.w3.org/2001/XMLSchema#string

He-Juan Cheng

http://www.w3.org/2001/XMLSchema#string

Jian-Chun Zhao

http://www.w3.org/2001/XMLSchema#string

Wen-Bao Li

http://www.w3.org/2001/XMLSchema#string

Yang-Yang Chu

http://www.w3.org/2001/XMLSchema#string

Zhen-Hua Tian

http://www.w3.org/2001/XMLSchema#string

P2860

Density-functional exchange-energy approximation with correct asymptotic behavior

Inhomogeneous Electron Gas

Self-Consistent Equations Including Exchange and Correlation Effects

Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Computational insights into the inhibitory mechanism of human AKT1 by an orally active inhibitor, MK-2206

Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma

Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trials.

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

P304

609-617

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/CBDD.12984

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yan-Yan Chu

P577

2017-05-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28338292

http://www.w3.org/2001/XMLSchema#string

Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

about

P2860

P2860

Rational drug design of indazole-based diarylurea derivatives as anticancer agents.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698